See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Injection Site Awareness Week

Dr. Stuart Bootle, MB ChB

Injection Site Awareness Week

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Kelly Close

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Bydureon

Updated 6 weeks ago
FDA Backtracks Over GLP-1s' Effects on Pancreas
Mar 4, 2014 | 
The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer.
Weekly Type 2 Drug to Be Delivered Via Needle Patch
Feb 24, 2014 | 
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

The i-port®

Davida Kruger and KK Patton

The i-port®

Injection Site Awareness Week

Dr. Stuart Bootle, MB ChB

Injection Site Awareness Week

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Kelly Close

Close Encounter - A Profile of a Diabetes Patient and Business Insider

An Update on Bydureon
Feb 17, 2012 | 
You've heard of the blockbuster drug Byetta, a daily injection for type 2 diabetes? Byetta's sister product, Bydureon, which is injected just once a week, has just been approved by the FDA and is available in pharmacies.
FDA Gives Long-Awaited Nod to Amylin’s Bydureon
Feb 3, 2012 | 
After several years of delays and setbacks, Amylin Pharmaceuticals has received FDA approval to begin US marketing of BydureonTM. The first once-a-week type 2 therapy to be offered in the US market, Bydureon is expected to be available by February. Amylin says that its wholesale price will be about $4,200 a year.

Fatal error: Call to a member function getUrl() on a non-object in /home/diabetes/public_html/browse.php on line 54